IgG, IgM, SRBD SARS

Cov-2
Created by : Nisa Kamilia Elsandra (Lia)
 Antigen

• Merupakan substansi yang dapat menginduksi respon

imun

• Bagian antigen yang berinteraksi dengan antibodi :

epitop / antigen determinant

• Bahan yang dapat dianalisis sebagai antigen:

• Mikroba patogen dan toksin mikroba
• Toksin tanaman dan hewan
• Protein spesifik atau senyawa lain yang berstruktur spesifik
• Senyawa obat (narkotik, psikotropik)
• Senyawa pestisida
 Antibodi

• Protein terlarut yang

diproduksi oleh sel B
sebagai respon terhadap
antigen

• Memiliki tiga fungsi:

netralisasi, opsonisasi, dan
aktivasi komplemen
Antibodi
 Antibodi
Immunoglobulin dibagi
menjadi 5 kelas: IgG,
IgD, IgA, IgM, dan IgE.
SARS-
CoV-2
Spike （ S ）
high specificity, mixed polypeptide,
antibody testing
Nucleocapsid （ N ）
Core protein, rich and
consecutive
appear early ACE-2
Membrane （ M Receptor
）
Envelope （ E
）
Genome RNA

The Severe acute respiratory syndrome coronavirus 2 (SARS-

CoV-2) is responsible for coronavirus disease 2019 (COVID-19)
is a CoV species. COVID virus contains four structural proteins;
spike (S), nucleocapsid (N), envelope (E) and membrane (M)
proteins and Genome (RNA)
Marco Cascella, etc.Features, Evaluation and Treatment Coronavirus(COVID-19)
 SARS-
CoV-2
H1

S2
H2 Spike
protein
Receptor Binding
Domain
(RBD) S1

Spike protein consists of two domains, namely S1 and S2, which are responsible for the binding step.
S1 domain contains Receptor Binding Domain (RBD) protein which is involved in host cell receptor
recognition and binding, whereas S2 domain contain the putative fusion peptide as well as heptad
repeat HR1 and HR2.
Prévost J, Gasser R, Beaudoin-Bussières G, Richard J, Duerr R, Laumaea A, Anand SP, Goyette G, Benlarbi M, Ding S, Medjahed H. Cross-sectional evaluation of humoral responses
against SARS-CoV-2 Spike. Cell Reports Medicine. 2020 Sep 30:100126.
Galipeau et al, 2020. Front. Immunol., 18 December 2020 | https://doi.org/10.3389/fimmu.2020.610688
 Imunokromatogra
fi (Rapid)
Antibodi
Immunoassay
(CLIA)
Chemiluminescence Immunoassays (CLIA)

• Antibodi spesifik dikonjugasikan dengan pewarna chemiluminescence

• 2 kelompok luminesens
- Bioluminesens → dari organisme hidup seperti kunang2
- Chemiluminesens → ditimbulkan oleh reaksi kimia sederhana dan aksi
dari oksigen atau peroksida
MR
• Serology test kits of COVID-19 on Mindray CLIA systems:
1. SARS-CoV-2 IgM (CLIA)
2. SARS-CoV-2 IgG (CLIA)

Running in Fully Automatic Machine

Mindray CL- Series,
With Chemilumenescence (CLIA)
Technology

Small Package : 2*50 tests/kit Time to first result : 29 minutes

Principle : Sandwich CLIA (GLOW CLIA) Sample volume : 10 μL
Sample type : Serum Shelf life : 2-8°C ， 6 months

SARS-CoV-2 IgM SARS-CoV-2 IgG

Sensitivity Up to 91.5 % Sensitivity Up to 97.9 %
Specificity Up to 100 % Specificity Up to 100 %
 IgG
IgM

blood
Ab in
Ab Test Result – CLIA Mindray

Infection IgM & IgG Pattern

SARS-CoV-2 IgM (CLIA) SARS-CoV-2 IgG (CLIA)

IgM - acute phase (several days after initial infection) IgG - later than IgM, much more effective, protective
Result : Reactive, with COI ≧ 1 Resut : Reactive , with Unit ≧ 10 U/ml
Non Reactive, with COI < 1 Non Reactive, with Unit < 10
U/ml
Prinsiple test of Mindray SARS CoV-2 RBD IgG (CLIA)

Performance
Reagent Name
CL-1000i Sensitivity Specificity

92.5 100.0
RBD IgG
（ 79.6 - 98.4 ） （ 98.3 - 100.0 ）

AP :
 Target of IgG S-RBD and
Total Abs

Spike
Schematic mechanism of the
neutralizing antibodies.
Competition of the neutralizing
antibody with the receptor
(ACE2) for binding to the Target of NAbs

receptor-binding domain (RBD) of

• Neutralizing antibody is targeting special sites of S-RBD
the SARS-CoV-2 Spike protein is
• S-RBD IgG is targeting the whole sequence of RBD, BUT only
shown.
detect IgG type
The protruding portion (violet) of
• Total antibody is targeting the whole sequence of RBD, AND
RBD is both the ACE2 receptor-
detect IgM, IgG and IgA together
binding site and the antibody
epitope. Wang D, Mai J, Zhou W, Yu W, Zhan Y, Wang N, Epstein ND, Yang Y. Immunoinformatic analysis of T-and
B-cell epitopes for SARS-CoV-2 vaccine design. Vaccines. 2020 Sep;8(3):355.
Zhou G, Zhao Q. Perspectives on therapeutic neutralizing
antibodies against the Novel Coronavirus SARS-CoV-2.
International Journal of Biological Sciences.
2020;16(10):1718.
6